RPID SEC Filings - Rapid Micro Biosystems, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1380106

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rapid Micro Biosystems, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

August 12, 2025	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results •Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. ◦Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. •Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compare
August 12, 2025	EX-10.3	Form of Warrant issued by the Registrant in connection with the Loan and Security Agreement, dated as of August 8, 2025, between the Registrant, Trinity Capital Inc. and the other parties thereto. Exhibit 10.3 Execution Version THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH S
August 12, 2025	EX-99.2	Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. Exhibit 99.2 Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. •$20 million drawn down at closing, with access to up to an additional $25 million •Strengthens Company’s financial position and reinforces ability to achieve positive cash flow Lexington, Mass., August 12, 2025 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Com
August 12, 2025	EX-10.1	Third Amendment to Rapid Micro Biosystems, Inc. 2023 Inducement Plan Inducement Plan Amendment *** THIRD AMENDMENT TO RAPID MICRO BIOSYSTEMS, INC. 2023 INDUCEMENT PLAN A. The Rapid Micro Biosystems, Inc. 2023 Inducement Plan, as may be amended from time to time (the “2023 Plan”), is hereby amended by deleting the paragraph in Section 11.23 in its entirety and substituting the following in lieu thereof: “11.23 Overall Share Limit” means 1,473,987 Shares.” B. The eff
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2025 RAPID MICRO BIOSYS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organ
August 12, 2025	EX-10.2	Loan and Security Agreement, dated as of August 8, 2025, between the Registrant, Trinity Capital Inc. and the other parties thereto. Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. EXECUTION VERSION LOAN AND SECURITY AGREEMENT DATED AS OF August 8, 2025 among RAPID MICRO BIOSYSTEMS, INC., as Borrower, THE LENDERS FROM TIME TO TIME PARTY
June 17, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organi
June 17, 2025	EX-99.1	Dear RMB Team Members and Shareholders: Exhibit 99.1 Dear RMB Team Members and Shareholders: I am writing on a personal note to let you know that I was recently diagnosed with a treatable form of Lymphoma. The good news is that I have an excellent care team and my doctors have given me a very good prognosis. I have already started treatment, which is expected to last approximately four months. During this period, while my in-person time
May 29, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 25 Hartwell Avenue, Lexington, MA 02421 (Address of
May 29, 2025	EX-1.01	Conflict Minerals Report of Rapid Micro Biosystems, Inc. EXHIBIT 1.01 Rapid Micro Biosystems, Inc. Conflict Minerals Report For the reporting period from January 1, 2024 to December 31, 2024 Rapid Micro Biosystems, Inc. (“we”, “us” or the “Company”) presents this Conflict Minerals Report (“CMR”) for the reporting period from January 1, 2024 to December 31, 2024 (“Reporting Year 2024”) in accordance with Rule 13p-1 (the “Rule”) under the U.S. Securities
May 23, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organiz
May 9, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organiza
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 9, 2025	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports First Quarter 2025 Financial Results •Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. ◦Reports record quarterly service revenue led by strong validation activity. •Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter
April 8, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 8, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 4, 2025	EX-99.1	Rapid Micro Biosystems TD Cowen 45th Annual Health Care Conference Robert Spignesi, President & CEO March 4, 2025 R A P I D M I C R O B I O S Y S T E M S N A S D A Q : R P I D © 2025, Rapid Micro Biosystems, Inc. \| RAPID MICRO BIOSYSTEMS® and GROWTH Rapid Micro Biosystems TD Cowen 45th Annual Health Care Conference Robert Spignesi, President & CEO March 4, 2025 R A P I D M I C R O B I O S Y S T E M S N A S D A Q : R P I D © 2025, Rapid Micro Biosystems, Inc.
March 4, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organi
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-3.1	Restated Certificate of Incorporation, as amended on May 23, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K (File No. 001-40592) filed on February 28, 2025) Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. The name of the corporation is Rapid Micro Biosystems, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 29, 2006. This Restated Certificate of Incorporation of the corporation, which restates an
February 28, 2025	EX-FILING FEES	Fee Filing Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Rapid Micro Biosystems, Inc.
February 28, 2025	EX-10.22	Distribution and Collaboration Agreement, dated February 21, 2025, by and between the Registrant and Millipore S.A.S. CERTAIN PORTIONS OF THIS EXHIBIT THAT ARE NOT MATERIAL AND CONTAIN INFORMATION THAT THE ISSUER CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL WERE OMITTED AND REPLACED WITH “[***]”.
February 28, 2025	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Consolidated Statements of Operations (In thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance •Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue increased by 27% compared to the fourth quarter of 2023. •Announces full year 2024 total revenue of $28.1 million, representing 25% gro
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40
February 28, 2025	EX-10.21	Second Amendment to Rapid Micro Biosystems, Inc. 2023 Inducement Plan SECOND AMENDMENT TO RAPID MICRO BIOSYSTEMS, INC. 2023 INDUCEMENT PLAN A.The Rapid Micro Biosystems, Inc. 2023 Inducement Plan, as may be amended from time to time (the “2023 Plan”), is hereby amended by deleting the paragraph in Section 11.23 in its entirety and substituting the following in lieu thereof: “11.23 Overall Share Limit” means 1,031,000 Shares.” B.The effective date of this first Amend
February 28, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or or
February 27, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or or
February 27, 2025	EX-99.1	Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development.
January 16, 2025	EX-99.1	Rapid Micro Biosystems 43rd Annual J.P. Morgan Healthcare Conference Rob Spignesi, President & CEO January 16, 2025 R A P I D M I C R O B I O S Y S T E M S N A S D A Q : R P I D © 2025, Rapid Micro Biosystems, Inc. \| RAPID MICRO BIOSYSTEMS® and GROWT Rapid Micro Biosystems 43rd Annual J.P. Morgan Healthcare Conference Rob Spignesi, President & CEO January 16, 2025 R A P I D M I C R O B I O S Y S T E M S N A S D A Q : R P I D © 2025, Rapid Micro Biosystems, Inc. \| RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. Rapid Micro B
January 16, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
January 14, 2025	EX-99.1	Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue •Fourth quarter 2024 total revenue expected to be a record at approximately $8.
January 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2025 RAPID MICRO BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2025 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
November 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2024 RAPID MICRO BIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or or
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 1, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
November 1, 2024	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results •Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023 •Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 ◦Included a multi-system order at an additional
August 2, 2024	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results •Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023 •150th Growth Direct® system placed with an existing top 15 global pharma customer •First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customer •Gross margin impr
August 2, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organ
August 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
May 30, 2024	EX-1.01	Conflict Minerals Report of Rapid Micro Biosystems, Inc. EXHIBIT 1.01 Rapid Micro Biosystems, Inc. Conflict Minerals Report For the reporting period from January 1, 2023 to December 31, 2023 Rapid Micro Biosystems, Inc. (“we”, “us” or the “Company”) presents this Conflict Minerals Report (“CMR”) for the reporting period from January 1, 2023 to December 31, 2023 (“Reporting Year 2023”) in accordance with Rule 13p-1 (the “Rule”) under the U.S. Securities
May 30, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 1001 Pawtucket Boulevard West, Lowell, MA 01854 (Ad
May 24, 2024	EX-3.1	Amendment to Restated Certificate of Incorporation. Certificate of Amendment to the Restated Certificate of Incorporation of Rapid Micro Biosystems, Inc.
May 24, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organiz
May 3, 2024	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 3, 2024 (GLOBE NEWSWIRE) - Rapid Micro Biosyst
May 3, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 3, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organiza
April 9, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 9, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 27, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 1, 2024	EX-10.21	First Amendment to Rapid Micro Biosystems, Inc. 2023 Inducement Plan FIRST AMENDMENT TO RAPID MICRO BIOSYSTEMS, INC. 2023 INDUCEMENT PLAN A.The Rapid Micro Biosystems, Inc. 2023 Inducement Plan, as may be amended from time to time (the “2023 Plan”), is hereby amended by deleting the paragraph in Section 11.23 in its entirety and substituting the following in lieu thereof: “11.23 Overall Share Limit” means 555,000 Shares.” B.The effective date of this first Amendmen
March 1, 2024	EX-10.20	(incorporated by reference to Exhibit 10.20 to the Registrant’s Annual Report on Form 10-K (File No. 001-40592) filed on March 1, 2024) Rapid Micro Biosystems, Inc. Second Amended and Restated Non-Employee Director Compensation Program February 6, 2024 Non-employee members of the board of directors (the “Board”) of Rapid Micro Biosystems, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in thi
March 1, 2024	EX-FILING FEES	Fee Filing Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Rapid Micro Biosystems, Inc.
March 1, 2024	EX-19.1	(incorporated by reference to Exhibit 19.1 to the Registrant’s Annual Report on Form 10-K (File No. 001-40592) filed on March 1, 2024) Rapid Micro Biosystems, Inc. Second Amended and Restated Insider Trading Compliance Policy (As of March 9, 2023) This Second Amended and Restated Insider Trading Compliance Policy (this “Policy”) of Rapid Micro Biosystems, Inc. (the “Company”) consists of seven sections: •Section I provides an overview; •Section II sets forth the policies of the Company prohibiting insider trading; •Section III ex
March 1, 2024	S-8	As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration No.
March 1, 2024	EX-97.1	Compensation Recovery Policy for Executive Officers RAPID MICRO BIOSYSTEMS, INC. COMPENSATION RECOVERY POLICY FOR EXECUTIVE OFFICERS Adopted as of November 27, 2023 Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation f
March 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40
March 1, 2024	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Consolidated Statements of Operations (In thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 Delivered 2023 recurring revenue of $13.5 million, representing 23% growth compare
March 1, 2024	EX-99.4	First Amendment to Rapid Micro Biosystems, Inc. 2023 Inducement Plan FIRST AMENDMENT TO RAPID MICRO BIOSYSTEMS, INC. 2023 INDUCEMENT PLAN A.The Rapid Micro Biosystems, Inc. 2023 Inducement Plan, as may be amended from time to time (the “2023 Plan”), is hereby amended by deleting the paragraph in Section 11.23 in its entirety and substituting the following in lieu thereof: “11.23 Overall Share Limit” means 555,000 Shares.” B.The effective date of this first Amendmen
March 1, 2024	EX-4.7	Description of Capital Stock Exhibit 4.7 DESCRIPTION OF CAPITAL STOCK General The following description of the capital stock of Rapid Micro Biosystems, Inc. (the “Company,” “we,” “us,” and “our”) summarizes some of the terms of our restated certificate of incorporation (“certificate of incorporation”) and amended and restated bylaws (“bylaws”), our seventh amended and restated investors’ rights agreement, dated March 9, 2021
March 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2024 RAPID MICRO BIOSYST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organi
February 2, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
January 22, 2024	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. / Endeavour Medtech Growth II LP - SC 13G/A Passive Investment SC 13G/A 1 d737829dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Rapid Micro Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the
January 10, 2024	EX-99.1	Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue Full year 2023 total revenue expected to be between $22.
January 10, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
December 28, 2023	424B3	Up to $10,000,000 Class A Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-276081 PROSPECTUS Up to $10,000,000 Class A Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or TD Cowen, dated December 15, 2023, relating to shares of our Class A common stock, par value $0.01 per share, or Class A common stock, offered by this prospectus. In accorda
December 21, 2023	CORRESP	VIA EDGAR VIA EDGAR December 21, 2023 United States Securities and Exchange Commission Office of Industrial Applications and Services Division of Corporation Finance 100 F Street, N.
December 15, 2023	EX-4.7	Form of Subordinated Indenture between the Registrant and one or more trustees to be named Exhibit 4.7 RAPID MICRO BIOSYSTEMS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee
December 15, 2023	EX-1.2	Sales Agreement, dated December 15, 2023, by and among the Registrant and Cowen and Company, LLC Exhibit 1.2 Rapid Micro Biosystems, Inc. $50,000,000 of SHARES of CLASS A common stock SALES AGREEMENT December 15, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows: 1.            Issuance and S
December 15, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rapid Micro Biosystems, Inc.
December 15, 2023	EX-4.6	Form of Senior Indenture between the Registrant and one or more trustees to be named Exhibit 4.6 RAPID MICRO BIOSYSTEMS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s
December 15, 2023	S-3	As filed with the Securities and Exchange Commission on December 15, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 15, 2023.
November 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
November 3, 2023	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2023 Financial Results Reports third quarter 2023 total revenue of $6.1 million, representing growth of 30% compared to third quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022 LOWELL, Mass., November 3, 2023 (GLOBE NEWSWIRE) - Rapid Mic
November 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
September 26, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or o
September 19, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or o
August 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2023 RAPID MICRO BIOSYS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organ
August 4, 2023	EX-10.2	Amended and Restated Non-Employee Director Compensation Program Rapid Micro Biosystems, Inc. Amended and Restated Non-Employee Director Compensation Program July 14, 2023 Non-employee members of the board of directors (the “Board”) of Rapid Micro Biosystems, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program
August 4, 2023	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30% compared to full year 2022 LOWELL, Mass., August 4, 2023 (GLOBE NEWSWIRE) - Rapid Mi
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
July 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2023 RAPID MICRO BIOSYST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organi
July 18, 2023	EX-99.1	Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors Exhibit 99.1 Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare pr
May 15, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40
May 12, 2023	CORRESP	FOIA CONFIDENTIAL TREATMENT REQUESTED BY RAPID MICRO BIOSYSTEMS, INC. CORRESP 1 filename1.htm FOIA CONFIDENTIAL TREATMENT REQUESTED BY RAPID MICRO BIOSYSTEMS, INC. CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED PURSUANT TO 17 CFR 200.83 WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED IN THIS LETTER AS FILED VIA
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 8, 2023	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organiza
May 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2023 RAPID MICRO BIOSYSTEM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organiza
May 5, 2023	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports First Quarter 2023 Financial Results Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%, compared to full year 2022 LOWELL, Mass., May 5, 2023 (GLOBE NEWSWIRE) - Rapid Micro
May 4, 2023	EX-FILING FEES	Fee Filing Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Rapid Micro Biosystems, Inc.
May 4, 2023	EX-99.1	Rapid Micro Biosystems, Inc. 2023 Inducement Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-271659) filed on May 4, 2023). RAPID MICRO BIOSYSTEMS, INC. 2023 INDUCEMENT PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company or its Subsidiaries to accept employment and provide them with equity ownership opportunities and/or equity-linked compensatory opportunities. The Company i
May 4, 2023	S-8	As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No.
March 21, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 21, 2023	DEF 14A	Schedule 14A filed with the Commission on March TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 14, 2023	EX-FILING FEES	Fee Filing Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Rapid Micro Biosystems, Inc.
March 14, 2023	S-8	As filed with the Securities and Exchange Commission on March 14, 2023 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No.
March 10, 2023	EX-4.7	Exhibit 4.7 Exhibit 4.7 DESCRIPTION OF CAPITAL STOCK General The following description of the capital stock of Rapid Micro Biosystems, Inc. (the “Company,” “we,” “us,” and “our”) summarizes some of the terms of our restated certificate of incorporation (“certificate of incorporation”) and amended and restated bylaws (“bylaws”), our seventh amended and restated investors’ rights agreement, dated March 9, 2021
March 10, 2023	EX-10.21	Form of Performance Restricted Stock Unit Agreement under the Rapid Micro Biosystems, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.21 to the Registrant's Annual Report on Form 10-K (File No. 001-40592) filed on March 10, 2023) RAPID MICRO BIOSYSTEMS, INC. 2021 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of Rapid Micro Biosystems, Inc. (the “Company”). The Company has grante
March 10, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40
March 10, 2023	EX-10.20	Form of Retention Agreement [RAPID MICRO BIOSYSTEMS, INC. LETTERHEAD] March , 2023 [Insert Name] [Insert Address] Re: Retention Bonus Dear [Insert Name], Rapid Micro Biosystems, Inc. (the “Company”) is pleased to inform you that it has decided to award you a retention bonus in an aggregate amount of $ (the “Bonus”), subject to and in accordance with the terms of this letter agreement (the “Agreement”). Capitalized terms used
March 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2023 RAPID MICRO BIOSYST UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organi
March 3, 2023	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Consolidated Statements of Operations (In thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Guidance Reports fourth quarter 2022 commercial revenue of $4.4 million Reports full year 2022 commercial revenue of $17.1 million Delivered full year 2022 recurring commercial revenue of $11.0 million, representing 40% growth Provides full year 2023 commercial revenue guidan
February 14, 2023	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. Class A / D1 Capital Partners L.P. - RAPID MICRO BIOSYSTEMS, INC. Passive Investment SC 13G/A 1 p23-0544sc13ga.htm RAPID MICRO BIOSYSTEMS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat
February 14, 2023	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. Class A / Longitude Capital Partners II, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate
February 8, 2023	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. Class A / Colony Harvest Ltd - SC 13G/A Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 75340L104 (CUSI
January 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2023 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
January 11, 2023	EX-99.1	Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Exhibit 99.1 Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Full year 2022 commercial revenue expected to be between $17.0 million and $17.2 million Finished 2022 with approximately $140 million in cash and investments providing runway at least into 2026 Company to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023 LOW
December 1, 2022	EX-99.1	Rapid Micro Biosystems Concludes Review of Strategic Alternatives Exhibit 99.1 Rapid Micro Biosystems Concludes Review of Strategic Alternatives LOWELL, Mass., December 1, 2022 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the ?Company?), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its
December 1, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or org
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or or
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 10, 2022	EX-10.1	Separation Agreement, dated as of August 24, 2022, between Rapid Micro Biosystems, Inc. and Richard Keys Separation Agreement and Release This Separation Agreement and Release (?Agreement?) is made by and between Richard Keys (?Executive?) and Rapid Micro Biosystems, Inc.
November 10, 2022	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results Reports third quarter 2022 commercial revenue of $4.7 million Delivered year-over-year recurring revenue growth of 34% Reaffirms full year 2022 commercial revenue guidance of at least $17.0 million LOWELL, Mass., November 10, 2022 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the ?Company?), an innov
November 7, 2022	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. Class A / JPMORGAN CHASE & CO - FILING RAPID MICRO BIOSYSTEMS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A common stock, $0.01 par value per share (Title of Class of Securities) 75340L104 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
August 29, 2022	SC 13D/A	RPID / Rapid Micro Biosystems, Inc. Class A / KENNEDY LEWIS MANAGEMENT LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title and Class of Securities) 75340L104 (CUSIP Number) Anthony Pasqua Kennedy Lewis Management LP 111 W 33rd Street, Suite 1910 New York, NY 10120 (212) 782-3
August 12, 2022	EX-3.1	Certificate of Designations of Series A Junior Participating Cumulative Preferred Stock of the Registrant classifying and designating the Series A Junior Participating Cumulative Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form 8-A (File No. 001-40592) filed on August 12, 2022) Exhibit 3.1 CERTIFICATE OF DESIGNATIONS of SERIES A JUNIOR PARTICIPATING CUMULATIVE PREFERRED STOCK of RAPID MICRO BIOSYSTEMS, INC. RAPID MICRO BIOSYSTEMS, INC. a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY: Pursuant to the authority conferred upon th
August 12, 2022	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 RAPID MICRO BIOSYSTEMS, INC. (Exact name of r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 20-8121647 (State of incorporation (I.R.S. Employer or organization) Identification No.) 1001 Pawtucke
August 12, 2022	EX-3.2	Certificate of Designations of Series B Junior Participating Cumulative Preferred Stock of the Registrant classifying and designating the Series B Junior Participating Cumulative Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form 8-A (File No. 001-40592) filed on August 12, 2022) Exhibit 3.2 CERTIFICATE OF DESIGNATIONS of SERIES B JUNIOR PARTICIPATING CUMULATIVE PREFERRED STOCK of RAPID MICRO BIOSYSTEMS, INC. RAPID MICRO BIOSYSTEMS, INC. a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY: Pursuant to the authority conferred upon th
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 12, 2022	EX-99.2	Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value Rejects Unsolicited, Non-Binding Proposal from Kennedy Lewis Investment Management Adopts Limited Duration Stockholder Rights Plan Exhibit 99.2 ? ? Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value ? Rejects Unsolicited, Non-Binding Proposal from Kennedy Lewis Investment Management ? Adopts Limited Duration Stockholder Rights Plan ? LOWELL, Mass., Aug. 12, 2022 - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the ?Company?), an innovative life sciences technology company providing m
August 12, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S
August 12, 2022	EX-4.1	Stockholder Rights Agreement, dated as of August 11, 2022, between the Registrant and Computershare Trust Company, N.A., as Rights Agent (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form 8-A (File No. 001-40592) filed on August 12, 2022) Exhibit 4.1 Rapid Micro Biosystems, Inc. and Computershare Trust Company, N.A. as Rights Agent Stockholder Rights Agreement Dated as of August 11, 2022 Table of Contents Page Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 9 Section 3. Issue of Right Certificates 9 Section 4. Form of Right Certificates 11 Section 5. Countersignature and Registration 13 Section 6. Transfer,
August 12, 2022	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results ? Reports second quarter 2022 commercial revenue of $3.9 million ? Lowers full year 2022 commercial revenue guidance to at least $17.0 million ? Implements organizational restructuring plan to right-size cost structure with focus on enhancing commercial execution and key product developme
June 30, 2022	EX-99.1	Kennedy Lewis Investment Management LLC \| 111 West 33rd Street, Suite 1910, New York, NY 10120 Exhibit 99.2 June 30, 2022 Rapid Micro Biosystems, Inc. 1001 Pawtucket Boulevard West, Suite 280 Lowell, Massachusetts 01854 Attn: Jonathan Paris, SVP, Secretary and General Counsel Re: Non-Binding Proposal To the Board of Directors: Kennedy Lewis Investment Management LLC (“Kennedy Lewis”) is interested in discussing a potential acquisition of Rapid Micro Biosystems, Inc. (“RPID”). Kennedy Lewis
June 30, 2022	SC 13D	RPID / Rapid Micro Biosystems, Inc. Class A / KENNEDY LEWIS MANAGEMENT LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title and Class of Securities) 75340L104 (CUSIP Number) Anthony Pasqua Kennedy Lewis Management LP 111 W 33rd Street, Suite 1910 New York, NY 10120 (212) 782-34
May 26, 2022	8-K	Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S. E
May 19, 2022	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. Class A / KENNEDY LEWIS MANAGEMENT LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title of Class of Securities) 75340L104 (CUSIP Number) May 17, 2022 (Date of event which requires filing of this statement) Check the appropriate box to design
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2022	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports First Quarter 2022 Financial Results ? Reports first quarter 2022 commercial revenue of $4.2 million ? Reaffirms full year 2022 commercial revenue outlook range of $27 million to $32 million, representing growth of approximately 25% to 50% ? LOWELL, Mass., May 10, 2022 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the ?Company?), an inn
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S. E
April 8, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 8, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 29, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S.
March 24, 2022	EX-10.19	Seventh Amendment to Lease Agreement as amended, dated March 18, 2022, by and between the Registrant and Farley White Pawtucket, LLC Exhibit 10.19 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (?Amendment?) dated as of March 18, 2022 between Farley White Pawtucket, LLC, a Massachusetts limited liability company having an address c/o Farley White Management Company, LLC, 155 Federal Street, Suite 1800, Boston, MA 02110 (?Landlord?), and Rapid Micro Biosystems, Inc., a Delaware corporation having an address of 1001 P
March 24, 2022	EX-10.18	Form of Global Stock Option Grant Agreement under the Rapid Micro Biosystems, Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.18 to the Registrant's Annual Report on Form 10-K (File No. 001-40592) filed on March 24, 2022) Exhibit 10.18 ? RAPID MICRO BIOSYSTEMS, INC. 2021 INCENTIVE AWARD PLAN ? GLOBAL STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Global Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the ?Plan?) of Rapid Micro Biosystems, Inc. (the ?Company?). The Company has granted to the p
March 24, 2022	EX-10.16	2021 Incentive Award Plan UK Sub-Plan (incorporated by reference to Exhibit 10.16 to the Registrant's Annual Report on Form 10-K (File No. 001-40592) filed on March 24, 2022) Exhibit 10.16 RAPID MICRO BIOSYSTEMS, INC. 2021 INCENTIVE AWARD PLAN SUB-PLAN FOR UK EMPLOYEES 1. Purpose Pursuant to the powers granted to the Administrator in Article 10.5 of the Rapid Micro Biosystems Inc. 2021 Incentive Award Plan (as it may be amended or restated from time to time, the ?Plan?), the Administrator has adopted this Sub-Plan for UK employees (the ?Sub-Plan?). The purpose of the S
March 24, 2022	EX-10.17	Form of Global Restricted Stock Unit Agreement under the Rapid Micro Biosystems, Inc. 2021 Incentive Award Plan Exhibit 10.17 RAPID MICRO BIOSYSTEMS, INC. 2021 INCENTIVE AWARD PLAN GLOBAL RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Global Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the ?Plan?) of Rapid Micro Biosystems, Inc. (the ?Company?). The Company has gr
March 24, 2022	EX-4.6	Description of Capital Stock Exhibit 4.6 DESCRIPTION OF CAPITAL STOCK General The following description of the capital stock of Rapid Micro Biosystems, Inc. (the ?Company,? ?we,? ?us,? and ?our?) summarizes some of the terms of our restated certificate of incorporation (?certificate of incorporation?) and amended and restated bylaws (?bylaws?), our seventh amended and restated investors? rights agreement (?investors? rights a
March 24, 2022	EX-10.15	Employment Agreement, dated October 1, 2021, by and between the Registrant and Richard A. Keys Exhibit 10.15 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of October 1, 2021 (the ?Effective Date?), is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Richard Keys (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?). RECITALS A. I
March 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 16, 2022	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / KENNEDY LEWIS MANAGEMENT LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title of Class of Securities) 75340L104 (CUSIP Number) March 7, 2022 (Date of event which requires filing of this statement) Check the appropriate box to design
March 4, 2022	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2021 Financial Results and Reaffirms Full Year 2022 Guidance ? Reports fourth quarter 2021 total revenue of $5.2 million and commercial revenue of $4.9 million ? Reports full year 2021 total revenue of $23.2 million and commercial revenue of $21.6 million ? Reaffirms full year 2022 commercial revenue outlook range of $27 mill
March 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S.
February 15, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.
February 15, 2022	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / Longitude Capital Partners II, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value per share (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de
February 14, 2022	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / Bain Capital Life Sciences Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.
February 14, 2022	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / D1 Capital Partners L.P. - RAPID MICRO BIOSYSTEMS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 11, 2022	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / Colony Harvest Ltd - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 75340L104 (CUSIP
February 11, 2022	EX-99	JOINT FILING AGREEMENT Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G.
February 2, 2022	SC 13G/A	RPID / Rapid Micro Biosystems, Inc. Class A / Endeavour Medtech Growth II LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Rapid Micro Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 26, 2022	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / JPMORGAN CHASE & CO - FILING RAPID MICRO BIOSYSTEMS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rapid Micro Biosystems, Inc. (Name of Issuer) Class A common stock, $0.01 par value per share (Title of Class of Securities) 75340L104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropri
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2022 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S
January 10, 2022	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Components of Preliminary Unaudited Revenue (in millions) Exhibit 99.1 Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook ? Full year 2021 commercial revenue expected to be between $21.3 million and $21.7 million Full year 2022 commercial revenue outlook between $27 million and $32 million Company to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 13,
December 23, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2021 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R
December 23, 2021	EX-99.1	Rapid Micro Biosystems Announces Appointment of Inese Lowenstein to Board of Directors Exhibit 99.1 Rapid Micro Biosystems Announces Appointment of Inese Lowenstein to Board of Directors ? LOWELL, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the ?Company?), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pl
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2021 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S. Em
November 12, 2021	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) EX-99.1 2 rpid-20211111ex99153681e.htm EX-99.1 Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2021 Financial Results Reports third quarter 2021 total revenue of $6.9 million and commercial revenue of $6.3 million Reaffirms full-year 2021 commercial revenue outlook of at least $24.0 million, representing at least 70% year-over-year growth LOWELL, Mass., November 11, 2021 (GLOBE NEWSWIRE)
September 23, 2021	EX-10.1	Payoff Letter, entered into as of September 17, 2021, by and between Rapid Micro Biosystems, Inc. and Kennedy Lewis Management LP, as collateral agent. EX-10.1 2 tmb-20210917xex10d1.htm EX-10.1 Exhibit 10.1 September 17, 2021 RAPID MICRO BIOSYSTEMS, INC. 1001 Pawtucket Blvd. West, Suite 280 Lowell, Massachusetts 01854 Attention: Sean Wirtjes, Chief Financial Officer Email: With a copy to: LATHAM & WATKINS LLP 200 Clarendon Street Boston, Massachusetts 02116 Attention: Stephen Ranere Facsimile: (617) 948-6001 Email: Re: Payoff Letter Ladies and Ge
September 23, 2021	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2021 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.
August 30, 2021	SC 13G	RPID / Rapid Micro Biosystems, Inc. Class A / Endeavour Medtech Growth II LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Rapid Micro Biosystems, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 75340L104 (CUSIP Number) July 14, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
August 27, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 26, 2021	EX-99.1	RAPID MICRO BIOSYSTEMS, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2021 Financial Results and Provides Business Update and Full Year 2021 Outlook Reports second quarter 2021 commercial revenue of $5.7 million, representing 135% year-over-year growth Issues full-year 2021 outlook for commercial revenue of at least $24.0 million, representing at least 70% year-over-year growth LOWELL, Mass., August 26, 2021
August 26, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2021 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction (Commission (I.R.S. Empl
July 21, 2021	EX-3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-40952) filed on July 21, 2021) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF RAPID MICRO BIOSYSTEMS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDUR
July 21, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2021 RAPID MICRO BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40592 20-8121647 (State or other jurisdiction of incorporation or organi
July 21, 2021	EX-3.1	Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-40952) filed on July 21, 2021) Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. The name of the corporation is Rapid Micro Biosystems, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 29, 2006. This Restated Certificate of Incorporation of the corporation, which restates an
July 16, 2021	424B4	Per share TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(4)? ?Registration No. 333-257431? Prospectus 7,920,000 shares Rapid Micro Biosystems, Inc. Class A Common stock ? This is an initial public offering of shares of Class A common stock by Rapid Micro Biosystems, Inc. Prior to this offering, there has been no public market for our shares of Class A common stock. The initial public offering price is $20
July 16, 2021	S-8	As filed with the Securities and Exchange Commission on July 16, 2021 As filed with the Securities and Exchange Commission on July 16, 2021 Registration No.
July 16, 2021	EX-4.3	Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of the Registrant’s initial public offering of its Common Stock). Exhibit 4.3 RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. The name of the corporation is Rapid Micro Biosystems, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 29, 2006. This Restated Certificate of Incorporation of the corporation, which restates an
July 14, 2021	S-1MEF	As filed with the Securities and Exchange Commission on July 14, 2021 As filed with the Securities and Exchange Commission on July 14, 2021 Registration No.
July 12, 2021	EX-10.10	Employment Agreement, dated July 8, 2021, by and between the Registrant and Sean Wirtjes (incorporated by reference to Exhibit 10.10 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) EX-10.10 12 tm219739d12ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 Employment Agreement This Employment Agreement (this “Agreement”), dated as of July 8, 2021, is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Sean Wirtjes (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a
July 12, 2021	EX-3.4	Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering) Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF RAPID MICRO BIOSYSTEMS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDUR
July 12, 2021	EX-10.12	Employment Agreement, dated July 8, 2021, by and between the Registrant and Victoria Vezina (incorporated by reference to Exhibit 10.12 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) Exhibit 10.12 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 8, 2021, is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Victoria Vezina (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all
July 12, 2021	EX-10.2	Rapid Micro Biosystems, Inc. 2021 Incentive Award Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) EX-10.2 7 tm219739d12ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 RAPID MICRO BIOSYSTEMS, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensator
July 12, 2021	EX-3.3	Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering) Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. The name of the corporation is Rapid Micro Biosystems, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on December 29, 2006. This Restated Certificate of Incorporation of the corporation, which restates an
July 12, 2021	S-1/A	Form S-1, as amended (Reg. No. 333-257431) TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 12, 2021 Registration No.
July 12, 2021	EX-10.9	Employment Agreement, dated July 8, 2021, by and between the Registrant and Robert Spignesi (incorporated by reference to Exhibit 10.9 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021 EX-10.9 11 tm219739d12ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 Employment Agreement This Employment Agreement (this “Agreement”), dated as of July 8, 2021, is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Robert Spignesi (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “
July 12, 2021	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 Rapid Micro Biosystems, Inc. [?] Shares of Class A Common Stock Underwriting Agreement , 2021 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY
July 12, 2021	EX-10.4	Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) Exhibit 10.4 Rapid Micro Biosystems, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the ?Board?) of Rapid Micro Biosystems, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be ma
July 12, 2021	CORRESP	July 12, 2021 July 12, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 12, 2021	EX-10.11	Employment Agreement, dated July 8, 2021, by and between the Registrant and John Wilson (incorporated by reference to Exhibit 10.11 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) EX-10.11 13 tm219739d12ex10-11.htm EXHIBIT 10.11 Exhibit 10.11 Employment Agreement This Employment Agreement (this “Agreement”), dated as of July 8, 2021, is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and John Wilson (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “
July 12, 2021	EX-10.13	mployment Agreement, dated July 8, 2021, by and between the Registrant and Jonathan Paris (incorporated by reference to Exhibit 10.13 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) Exhibit 10.13 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of July 8, 2021, is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Jonathan Paris (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all,
July 12, 2021	EX-3.1(1)	Certificate of Amendment to Certificate of Incorporation of the Registrant (currently in effect) (incorporated by reference to Exhibit 3.1.1 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021). EX-3.1(1) 3 tm219739d12ex3-1d1.htm EXHIBIT 3.1(1) Exhibit 3.1(1) CERTIFICATE OF AMENDMENT TO NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. Rapid Micro Biosystems, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: That the Board of Directors
July 12, 2021	EX-10.6	Form of Indemnification Agreement for Directors and Executive Officers (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) Exhibit 10.6 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of [], 2021 between Rapid Micro Biosystems, Inc., a Delaware corporation (the ?Company?), and [] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided
July 12, 2021	EX-10.3	Rapid Micro Biosystems, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on July 12, 2021) EX-10.3 8 tm219739d12ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 RAPID MICRO BIOSYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN Article I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Comp
July 12, 2021	CORRESP	[Signature Page Follows] July 12, 2021 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 12, 2021	8-A12B	Form 8-A (File No. 001-40592) filed with the Commission on July 12, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-8121647 (State of incorporation or organization) (I.R.S. Employer Identification No.) 1001 Pawtucket
June 25, 2021	EX-3.1	Certificate of Incorporation of the Registrant, as amended (currently in effect) Exhibit 3.1 NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Rapid Micro Biosystems, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CER
June 25, 2021	EX-4.2	Forms of Common Stock Warrant Agreements (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) Exhibit 4.2 Schedule of Holders of Warrants to Purchase Common Stock Holder Name KPCB Holdings, Inc. Longitude Venture Partners II, L.P. Quaker BioVentures II, L.P. TPG RAMB Holdings, L.P. THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWIS
June 25, 2021	EX-10.15	Loan and Security Agreement, dated May 14, 2020, among the Registrant, Kennedy Lewis Capital Partners Master Fund II LP, as lender, and Kennedy Lewis Management LP, as collateral agent Exhibit 10.15 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of May 14, 2020 (the “Effective Date”) among Kennedy Lewis Management LP (“KLIM”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Age
June 25, 2021	EX-21.1	Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) Exhibit 21.1 Subsidiaries of Rapid Micro Biosystems, Inc. Legal Name of Subsidiary Jurisdiction of Organization Rapid Micro Biosystems Europe GmbH Germany Rapid Micro Biosystems Services Switzerland LLC Switzerland
June 25, 2021	EX-4.1	Specimen Stock Certificate evidencing the shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021 EX-4.1 4 tm219739d9ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 FULLY-PAID AND NON-ASSESSABLE SHARES OF CLASS A COMMON STOCK OF Rapid Micro Biosystems, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held
June 25, 2021	EX-4.4	Form of Series B1 Warrant Agreement (incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) EX-4.4 7 tm219739d9ex4-4.htm EXHIBIT 4.4 Exhibit 4.4 Schedule of Holders of Warrants to Purchase Series B1 Preferred Stock Of Rapid Micro Biosystems, Inc. Holder Number of Shares Issuance Date Expiration Date Foster & Foster Capital V LLC 19,354 December 6, 2017 December 6, 2027 Foster & Foster Capital V LLC 19,354 January 17, 2018 January 17, 2028 Longitude Venture Partners II, L.P. 322,580 Decem
June 25, 2021	EX-10.8	Sublease, dated June 8, 2021, by and between the Registrant and National Medical Care, Inc. Exhibit 10.8 SUBLEASE Effective as of June 8, 2021 (the “Effective Date”), NATIONAL MEDICAL CARE, INC., a Delaware corporation, (“Sublandlord”), and RAPID MICRO BIOSYSTEMS, INC., a Delaware corporation (“Subtenant”), hereby agree as follows: 1. Overlease. As used herein, the term “Overlease” shall mean that certain Lease, dated as of June 21, 2019, by and between DUFFY HARTWELL LLC., a Massachuset
June 25, 2021	EX-10.1	Rapid Micro Biosystems, Inc. 2010 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) Exhibit 10.1 RAPID MICRO BIOSYSTEMS, INC. 2010 STOCK OPTION AND GRANT PLAN (as amended and restated April 28, 2020) SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Rapid Micro Biosystems, Inc. 2010 Stock Option and Grant Plan (as amended and restated, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and
June 25, 2021	EX-4.5	Form of Series C1 Warrant Agreement (incorporated by reference to Exhibit 4.5 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) Exhibit 4.5 Execution Version NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE ACT AND APPLICABLE LAWS. Warrant
June 25, 2021	EX-4.3	Form of Series A1 Warrant Agreement (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) EX-4.3 6 tm219739d9ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 Schedule of Holders of Warrants to Purchase Series A1 Preferred Stock Of Rapid Micro Biosystems, Inc. Holder Number of Shares Issuance Date Expiration Date Foster & Foster Capital V LLC 39,266 July 24, 2017 July 24, 2027 Longitude Venture Partners II, L.P. 2,500,000 July 24, 2017 July 24, 2027 Mellon Family Investment Company V 273,227 July 24,
June 25, 2021	EX-3.2	Bylaws of the Registrant (currently in effect) Exhibit 3.2 BYLAWS OF RAPID MICRO BIOSYSTEMS, INC. ARTICLE 1 OFFICES SECTION 1.01. Registered Office. The registered office of Rapid Micro Biosystems, Inc., a Delaware corporation (the "Corporation"), in the State of Delaware shall be located at 1209 Orange Street, in the City of Wilmington, County of New Castle. The name and of the Corporation's registered agent at such address is The Corporation
June 25, 2021	S-1	Form S-1, as amended (File No. 333-257431), initially filed with the SEC by the Registrant on June 25, 2021 TABLE OF CONTENTS? As filed with the Securities and Exchange Commission on June 25, 2021 Registration No.
June 25, 2021	EX-10.14	License Agreement, dated May 13, 2013 (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) Exhibit 10.14 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. PATENT LICENSE AGREEMENT This Agreement is made and entered into as of the 13th day of May, 2013 (?Effective Date?) by and between Thermo CRS, Ltd., a Cana
June 25, 2021	EX-10.7	Lease Agreement, dated October 21, 2013, by and between the Registrant and Farley White Pawtucket, LLC, as amended (incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) EX-10.7 11 tm219739d9ex10-7.htm EXHIBIT 10.7 Exhibit 10.7 LEASE 1001 PAWTUCKET, L.L.C., LANDLORD TO RAPID MICRO BIOSYSTEMS, INC., TENANT This LEASE made as of the Date of Lease by and between Landlord and Tenant. 1. Basic Lease Terms and Certain Defined Terms. Date of Lease: As of October 21, 2013 Landlord: 1001 Pawtucket, L.L.C., a Delaware limited liability company, having an address c/o Winstan
June 25, 2021	EX-10.5	Seventh Amended and Restated Investors' Rights Agreement (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-257431) filed on June 25, 2021) EX-10.5 10 tm219739d9ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 Execution Version RAPID MICRO BIOSYSTEMS, INC. SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 9, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration 6 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 9 2.5 Furnish Information 10 2.6 Expenses o
June 25, 2021	CORRESP	* * * 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris June 25, 2021 Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C
June 10, 2021	EX-10.13	LOAN AND SECURITY AGREEMENT Exhibit 10.13 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of May 14, 2020 (the ?Effective Date?) among Kennedy Lewis Management LP (?KLIM?), as collateral agent (in such capacity, together with its successors and assigns in such capacity, ?Collateral Age
June 10, 2021	EX-10.12	PATENT LICENSE AGREEMENT EX-10.12 3 filename3.htm Exhibit 10.12 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. PATENT LICENSE AGREEMENT This Agreement is made and entered into as of the 13th day of May, 2013 (“Effective Date”) by and between
June 10, 2021	DRS/A	As confidentially submitted to the Securities and Exchange Commission on June 9, 2021, as Amendment No. 2 to the Draft Registration Statement submitted to the Securities and Exchange Commission on March 22, 2021 TABLE OF CONTENTS? As confidentially submitted to the Securities and Exchange Commission on June 9, 2021, as Amendment No.
June 10, 2021	EX-10.7	LEASE 1001 PAWTUCKET, L.L.C., LANDLORD RAPID MICRO BIOSYSTEMS, INC., TENANT Exhibit 10.7 LEASE 1001 PAWTUCKET, L.L.C., LANDLORD TO RAPID MICRO BIOSYSTEMS, INC., TENANT This LEASE made as of the Date of Lease by and between Landlord and Tenant. 1. Basic Lease Terms and Certain Defined Terms. Date of Lease: As of October 21, 2013 Landlord: 1001 Pawtucket, L.L.C., a Delaware limited liability company, having an address c/o Winstanley Enterprises, Inc., 150 Baker Avenue Exten
June 9, 2021	DRSLTR	* * * 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris June 9, 2021 Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C.
May 7, 2021	DRSLTR	* * * May 7, 2021 VIA EDGAR 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washing
May 7, 2021	DRS/A	As confidentially submitted to the Securities and Exchange Commission on May 7, 2021, amending the Draft Registration Statement submitted to the Securities and Exchange Commission on March 22, 2021 TABLE OF CONTENTS? As confidentially submitted to the Securities and Exchange Commission on May 7, 2021, amending the Draft Registration Statement submitted to the Securities and Exchange Commission on March 22, 2021 Registration No.
March 22, 2021	DRS	As confidentially submitted to the Securities and Exchange Commission on March 22, 2021 DRS 1 filename1.htm TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on March 22, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other
March 22, 2021	EX-3.2	RAPID MICRO BIOSYSTEMS, INC. ARTICLE 1 EX-3.2 3 filename3.htm Exhibit 3.2 BYLAWS OF RAPID MICRO BIOSYSTEMS, INC. ARTICLE 1 OFFICES SECTION 1.01. Registered Office. The registered office of Rapid Micro Biosystems, Inc., a Delaware corporation (the "Corporation"), in the State of Delaware shall be located at 1209 Orange Street, in the City of Wilmington, County of New Castle. The name and of the Corporation's registered agent at such add
March 22, 2021	EX-4.4	Schedule of Holders Warrants to Purchase Series B1 Preferred Stock Of Rapid Micro Biosystems, Inc. EX-4.4 5 filename5.htm Exhibit 4.4 Schedule of Holders of Warrants to Purchase Series B1 Preferred Stock Of Rapid Micro Biosystems, Inc. Holder Number of Shares Issuance Date Expiration Date Foster & Foster Capital V LLC 19,354 December 6, 2017 December 6, 2027 Foster & Foster Capital V LLC 19,354 January 17, 2018 January 17, 2028 Longitude Venture Partners II, L.P. 322,580 December 6, 2017 Decemb
March 22, 2021	EX-3.1	EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) EX-3.1 2 filename2.htm Exhibit 3.1 Execution Version EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAPID MICRO BIOSYSTEMS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Rapid Micro Biosystems, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “
March 22, 2021	EX-10.5	RAPID MICRO BIOSYSTEMS, INC. SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 9, 2021 TABLE OF CONTENTS EX-10.5 7 filename7.htm Exhibit 10.5 Execution Version RAPID MICRO BIOSYSTEMS, INC. SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 9, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 6 2.1 Demand Registration 6 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 9 2.5 Furnish Information 10 2.6 Expenses of Registration 10 2.7
March 22, 2021	EX-4.3	Schedule of Holders Warrants to Purchase Series A1 Preferred Stock Of Rapid Micro Biosystems, Inc. EX-4.3 4 filename4.htm Exhibit 4.3 Schedule of Holders of Warrants to Purchase Series A1 Preferred Stock Of Rapid Micro Biosystems, Inc. Holder Number of Shares Issuance Date Expiration Date Foster & Foster Capital V LLC 39,266 July 24, 2017 July 24, 2027 Longitude Venture Partners II, L.P. 2,500,000 July 24, 2017 July 24, 2027 Mellon Family Investment Company V 273,227 July 24, 2017 July 24, 2027
March 22, 2021	EX-21.1	Subsidiaries of Rapid Micro Biosystems, Inc. Legal Name of Subsidiary Jurisdiction of Organization Rapid Micro Biosystems Europe GmbH Germany Rapid Micro Biosystems Services Switzerland LLC Switzerland EX-21.1 8 filename8.htm Exhibit 21.1 Subsidiaries of Rapid Micro Biosystems, Inc. Legal Name of Subsidiary Jurisdiction of Organization Rapid Micro Biosystems Europe GmbH Germany Rapid Micro Biosystems Services Switzerland LLC Switzerland
March 22, 2021	EX-4.5	RAPID MICRO BIOSYSTEMS, INC. PREFERRED STOCK PURCHASE WARRANT (as amended and restated) EX-4.5 6 filename6.htm Exhibit 4.5 Execution Version NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE ACT AND A

RPID / Rapid Micro Biosystems, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)